Tectonic Therapeutic (TECX) Common Equity (2017 - 2026)

Tectonic Therapeutic (TECX) has reported Common Equity for 10 consecutive years, with $230.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity fell 23.46% year-over-year to $230.4 million; the TTM figure through Mar 2026 stood at $230.4 million (down 23.46% YoY), while the FY2025 annual figure was $251.3 million, up 78.53% from the prior year.
• Common Equity slipped to $230.4 million in Q1 2026 per TECX's latest filing, from $251.3 million in the prior quarter.
• Across five years, Common Equity topped out at $301.0 million in Q1 2025 and bottomed at -$99.6 million in Q1 2024.
• Historically, Common Equity has averaged $100.7 million across 5 years, with a median of $140.8 million in 2024.
• Annual changes were most pronounced in 2023 — Common Equity slumped 181.33% — and 2025, when it jumped 402.32%.
• Tectonic Therapeutic's Common Equity stood at -$45.7 million in 2022, then sank by 85.39% to -$84.6 million in 2023, then jumped by 266.33% to $140.8 million in 2024, then jumped by 78.53% to $251.3 million in 2025, then declined by 8.32% to $230.4 million in 2026.
• Business Quant data shows TECX's Common Equity at $230.4 million in Q1 2026, $251.3 million in Q4 2025, and $267.5 million in Q3 2025.